

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Klaus P. HIRTH
Title: METHOD FOR MOLECULAR DIAGNOSIS OF TUMOR ANGIOGENESIS AND METASTASIS
Appl. No.: To be assigned
Filing Date: April 11, 2001
Examiner: Unassigned
Art Unit: Unassigned



INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §1.56

Commissioner for Patents
Box PATENT APPLICATION
Washington, D.C. 20231

Sir:

Applicant submits herewith on Form PTO-1449 a listing of the documents cited by or submitted to the U.S. PTO in parent application Serial No. 09/336,650, filed 06/18/1999. As provided in 37 CFR §1.98(d), copies of the documents are not being provided since they were previously submitted to the United States Patent & Trademark Office in the above-identified parent application.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in 37 CFR §1.56(b). Applicant does not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* art reference against the claims of the present application.

TIMING OF THE DISCLOSURE

The list of documents is being submitted in compliance with 37 CFR §1.97(b), within three (3) months of the filing date of the application.

RELEVANCE OF EACH DOCUMENT

The relevance of the foreign-language documents is explained in the parent application.

Applicant respectfully requests that any listed document be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO-1449 be returned in accordance with MPEP §609.



The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 C.F.R. §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 19-0741. Should no proper payment be enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 19-0741.

Respectfully submitted,

Date April 11, 2001

FOLEY & LARDNER
Washington Harbour
3000 K Street, N.W., Suite 500
Washington, D.C. 20007-5109
Telephone: (202) 672-5475
Facsimile: (202) 672-5399

By


 Beth A. Burrous
Attorney for Applicant
Registration No. 35,087

Form PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 038602/1140		SERIAL NO. To be assigned		
INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i>				APPLICANT Klaus P. HIRTH				
				FILING DATE April 11, 2001		GROUP ART UNIT Unassigned		
U.S. PATENT DOCUMENTS								
EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE	
	A1	5,840,301	11/1998	Rockwell et al.	424	143.1		
	A2	3,927,193	12/1975	Hansen et al.	424	1		
	A3	5,474,755	12/1995	Hanna, Jr., et al.	424	1.49		
	A4	5,922,302	11/1998	Goldenberg et al.	424	1.41.		
	A5	5,849,479	11/1998	Janjic et al.	435	6		
FOREIGN PATENT DOCUMENTS								
	REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION	
							YES	NO
OTHER DOCUMENTS <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>								
	A6	Toi et al., Tumor angiogenesis in breast cancer: It's importance as a prognostic indicator and the association with vascular endothelial growth factor expression, Breast Cancer Research and Treatment, Vol. 36, pages 193-0204						
	A7	Battegay, Angiogenesis: mechanistic insights, neovascular diseases, and theraputic projects, Journal of Molecular Medicine, Vol. 73, pages 333-346						
	A8	Kendall et al., Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor, Proc. Natl. Sci., USA, Vol.90(22), pp. 10705-10709						
EXAMINER				DATE CONSIDERED				
* EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include any copy of this form with next communication to applicant.								

J1033 U.S. PTO
 09/829968
 04/11/01